2,732 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC bought a new stake in shares of Boston Scientific Co. (NYSE:BSXFree Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,732 shares of the medical equipment provider’s stock, valued at approximately $210,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. BOKF NA raised its stake in shares of Boston Scientific by 14.0% in the 2nd quarter. BOKF NA now owns 3,065 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 377 shares in the last quarter. Qsemble Capital Management LP bought a new position in shares of Boston Scientific in the second quarter valued at approximately $2,690,000. LPL Financial LLC raised its position in shares of Boston Scientific by 6.4% in the second quarter. LPL Financial LLC now owns 1,015,687 shares of the medical equipment provider’s stock valued at $78,218,000 after purchasing an additional 61,350 shares during the period. SP Asset Management LLC lifted its stake in shares of Boston Scientific by 7.7% in the second quarter. SP Asset Management LLC now owns 4,064 shares of the medical equipment provider’s stock worth $313,000 after buying an additional 292 shares during the last quarter. Finally, MGO One Seven LLC boosted its holdings in shares of Boston Scientific by 101.5% during the 2nd quarter. MGO One Seven LLC now owns 16,672 shares of the medical equipment provider’s stock worth $1,284,000 after buying an additional 8,399 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 20,949 shares of company stock valued at $1,627,877 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on BSX shares. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Raymond James increased their target price on Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research note on Wednesday, September 4th. The Goldman Sachs Group began coverage on Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 target price on the stock. Truist Financial upped their price target on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Finally, Mizuho raised their price target on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $85.38.

View Our Latest Analysis on BSX

Boston Scientific Stock Down 0.2 %

BSX opened at $82.87 on Thursday. The firm has a market cap of $121.58 billion, a price-to-earnings ratio of 69.64, a PEG ratio of 2.71 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm’s 50-day simple moving average is $77.79 and its 200-day simple moving average is $73.87. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $83.27.

Boston Scientific (NYSE:BSXGet Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The firm had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the prior year, the firm earned $0.53 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts anticipate that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.